Silyl-Lipid Cannabinoids for Selective CB2 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid therapies for neurodegenerative disorders face challenges in selective activation of the CB2 receptor to avoid psychoactive effects and have limitations in potency and bioavailability due to poor drug delivery and high doses required, necessitating the development of more potent and selective cannabinoid therapeutics.
Innovation Solution
Design and synthesis of silyl-lipid cannabinoids as carbon-silicon bioisosteres that exhibit selective and potent agonism towards the CB2 receptor, incorporating silicon to enhance lipophilicity and stability, thereby improving pharmacokinetic properties and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of CBD are administered to overcome poor bioavailability, then therapeutic effect may be achieved, but toxicity and patient compliance issues increase
Solution Approach 1:
The patent modifies the chemical structure of cannabinoids by replacing terminal methyl groups with silyl-lipid groups, changing the lipophilicity and metabolic stability parameters. This structural modification enables the compound to maintain therapeutic efficacy at lower doses while reducing toxicity, directly addressing the contradiction between achieving therapeutic effect and avoiding harm
2Ease of operation
If CBD is administered orally, then ease of administration is improved, but bioavailability remains poor at 6%
Solution Approach 1:
The silyl-lipid modification changes the physicochemical parameters of the cannabinoid, specifically increasing lipophilicity and resistance to metabolic degradation. This enables the compound to survive first-pass metabolism and achieve higher systemic exposure after oral administration, resolving the contradiction between ease of administration and bioavailability
3Reliability
If CB1 receptor is activated to achieve therapeutic effects, then neurological benefits are obtained, but psychoactive side effects occur
Solution Approach 1:
The patent designs compounds with specific structural features (silyl-lipid groups at particular positions) that create local structural quality differences. This enables selective binding to CB2 receptors while avoiding CB1 receptor activation, achieving neurological benefits without psychoactive side effects by targeting specific receptor subtypes
4Reliability
If selective CB2 agonists are designed to avoid psychoactive effects, then selectivity is improved, but the high structural similarity between CB1 and CB2 binding pockets makes differentiation challenging
Solution Approach 1:
The patent introduces silyl-lipid groups that significantly alter the steric and electronic parameters of the cannabinoid molecule. These parameter changes create sufficient structural differentiation to achieve CB2 selectivity despite the inherent similarity between CB1 and CB2 binding pockets, resolving the contradiction between selectivity and design complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The silyl-lipid cannabinoids demonstrate strong agonist activity and high selectivity towards CB2, offering improved therapeutic efficacy and bioavailability, potentially treating neurodegenerative disorders with reduced side effects and increased potency.
Implementation Method 1
There is a growing understanding that hydrophobic groups can be considered as pharmacophores and can be a significant element in the design of molecular probes and medicinal compounds, where it has been demonstrated that even the hydrophobic interaction of a protein residue and a single methyl group can stabilize binding as much as polar interactions
Implementation Method 2
incorporating silicon to enhance lipophilicity and stability, thereby improving pharmacokinetic properties and reducing toxicity
Data Source
AI summary
Provided herein are silyl lipid compounds that are cannabinoid analogs. The provided compounds are particularly useful for treating neurodegenerative disorders, and for alleviating symptoms associated with epilepsy and inflammation. Also provided are compositions and methods including the provided compounds.